 |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2, PHASE3 |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2, PHASE3 |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer | Hoffmann-La Roche | NA |
COMPLETED
(Sep 1, 2026)
| PHASE3 |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2, PHASE3 |
| A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2, PHASE3 |
| A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes | Hoffmann-La Roche | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease | Hoffmann-La Roche | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE1, PHASE2 |
| Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma | Hoffmann-La Roche | NA |
RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment | Hoffmann-La Roche | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants | Hoffmann-La Roche | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma | Hoffmann-La Roche | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |
| A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction | Hoffmann-La Roche | NA |
COMPLETED
(Aug 1, 2026)
| PHASE2 |
| A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy | Hoffmann-La Roche | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |
| A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) | Hoffmann-La Roche | NA |
COMPLETED
(Aug 1, 2026)
| PHASE3 |
| A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer | Hoffmann-La Roche | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Hoffmann-La Roche | NA |
TERMINATED
(Jul 1, 2026)
| PHASE1, PHASE2 |
| A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC) | Hoffmann-La Roche | NA |
TERMINATED
(Jul 1, 2026)
| PHASE1, PHASE2 |
| A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
| A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | Hoffmann-La Roche | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer | Hoffmann-La Roche | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
| A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE3 |
| A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE3 |
| A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer | Hoffmann-La Roche | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |
| A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy | Hoffmann-La Roche | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |
| A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants | Hoffmann-La Roche | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |
| A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma | Hoffmann-La Roche | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |
| A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer | Hoffmann-La Roche | NA |
COMPLETED
(May 1, 2026)
| PHASE2, PHASE3 |
| A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus | Hoffmann-La Roche | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE3 |
| A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | Hoffmann-La Roche | NA |
TERMINATED
(Apr 1, 2026)
| PHASE1, PHASE2 |
| An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma | Hoffmann-La Roche | NA |
TERMINATED
(Apr 1, 2026)
| PHASE1, PHASE2 |
| Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms | Hoffmann-La Roche | NA |
COMPLETED
(Apr 1, 2026)
| PHASE3 |
| A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer | Hoffmann-La Roche | NA |
TERMINATED
(Mar 1, 2026)
| PHASE2 |
